Advaxis News Releases

Date	Title and Summary	Additional Formats
October 15, 2020	Advaxis to Present Data from Ongoing ADXS-503 Phase 1/2 Clinical Trial at SITC 2020 PRINCETON, N.J., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Advaxis , Inc. (Nasdaq: ADXS ), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced it will present an ePoster at the 35 th Annual Meeting of the Society for	PDF Version
September 29, 2020	Advaxis, Inc. Adopts Limited Duration Stockholder Rights Plan PRINCETON, N.J., Sept. 29, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that its Board of Directors has approved the adoption of a limited duration	PDF Version
September 24, 2020	Advaxis Announces FDA Clearance of New IND for ADXS-504 for Treatment of Prostate Cancer Strategic transition to Investigator sponsored IND from previously announced Advaxis sponsored IND Initiation of investigator sponsored Phase 1 study of ADXS-504 in prostate cancer on-track for Q4 2020 PRINCETON, N.J., Sept. 24, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a	PDF Version
September 10, 2020	Advaxis Reports Third Quarter Ended July 31, 2020 Financial Results and Provides a Business Update Strategic expansion of ADXS-503 HOT program in NSCLC to explore potential to enhance and or restore sensitivity to checkpoint inhibitors Enrolling in Phase 1/2 Study efficacy expansion of ADXS-503 in NSCLC based on sustained and durable clinical responses in first two of three evaluable patients	PDF Version
September 4, 2020	Advaxis Announces Resignation of Chief Financial Officer PRINCETON, N.J., Sept. 04, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products today announced that Molly Henderson, Executive Vice President and Chief Financial Officer, has	PDF Version
August 27, 2020	Advaxis to Present Corporate Overview at the LD Micro 500 Virtual Conference PRINCETON, N.J., Aug. 27, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS ), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that Kenneth A. Berlin, President and Chief Executive Officer of Advaxis, will	PDF Version
August 3, 2020	Advaxis Announces Common Stock Purchase Agreement for up to $20 Million with Lincoln Park Capital PRINCETON, N.J., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products today announced that it has entered into a common stock purchase agreement for up to $20 million	PDF Version
June 23, 2020	Advaxis to be Featured in “Grand Rounds: a Webinar in Biotech and Specialty Pharma,” Hosted by Alliance Global Partners PRINCETON, N.J., June 23, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS ), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that Kenneth A. Berlin, President and Chief Executive Officer of Advaxis, will be	PDF Version
June 11, 2020	Advaxis Reports Second Quarter Ended April 30, 2020 Financial Results and Provides a Business Update Expanding Phase 1/2 Study of ADXS-503 in NSCLC based on sustained and durable clinical responses in first two patients from Part B combination arm with KEYTRUDA® Increasing patient enrollment in Part B and initiating Part C to move into first-line regimen with KEYTRUDA® in patients ineligible for	PDF Version
June 1, 2020	Advaxis to Host Second Quarter Financial Results and Business Update Conference Call on Thursday, June 11, 2020 PRINCETON, N.J., June 01, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, announced today that it will release financial results for the second quarter ended April 30,	PDF Version